Replies to post #423687 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

The 3rd row could also be stated as 338 - 263 = 75 that needed down titration corresponding to 21.5% of dose arms patients. Likely mostly from the 50mg arm.

Those target to take either 30 mg or 50 mg of blarcamesine per day 263 ( 78.5%)

This could mean that up to about 40% of the 50mg arm did not achieve their target maintenance dose, or some mix between the dose arms not reaching their 30mg or 50mg maintenance dose target. This would invalidate the statistics of reporting on dose arms, as originally intended, and instead the whole dataset becomes subject to subgroup analysis.